{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Repeat+Testing&page=39",
    "query": {
      "intervention": "Repeat Testing",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 1097,
    "total_pages": 110,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Repeat+Testing&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Repeat+Testing&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T19:47:49.628Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04941287",
      "title": "Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Distal Bile Duct Adenocarcinoma",
        "Metastatic Gallbladder Carcinoma",
        "Metastatic Intrahepatic Cholangiocarcinoma",
        "Recurrent Distal Bile Duct Adenocarcinoma",
        "Recurrent Gallbladder Carcinoma",
        "Recurrent Intrahepatic Cholangiocarcinoma",
        "Stage IV Distal Bile Duct Cancer AJCC v8",
        "Stage IV Gallbladder Cancer AJCC v8",
        "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8",
        "Unresectable Liver Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Varlilumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2021-12-15",
      "completion_date": "2026-04-29",
      "has_results": true,
      "last_update_posted_date": "2025-05-23",
      "last_synced_at": "2026-10-30T19:47:49.628Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04941287"
    },
    {
      "nct_id": "NCT03474874",
      "title": "Human Repeated Insult Patch Test",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dermatitis",
        "Allergy",
        "Contact Allergy"
      ],
      "interventions": [
        {
          "name": "NeoMatriX Collagen Dressing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "NeXtGen Biologics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 68,
      "start_date": "2018-02-26",
      "completion_date": "2018-04-06",
      "has_results": true,
      "last_update_posted_date": "2019-07-16",
      "last_synced_at": "2026-10-30T19:47:49.628Z",
      "location_count": 1,
      "location_summary": "Fairfield, New Jersey",
      "locations": [
        {
          "city": "Fairfield",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03474874"
    },
    {
      "nct_id": "NCT03082274",
      "title": "Prospective Validation of Prostate Biomarkers for Repeat Biopsy",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ConfirmMDx",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "SelectMDx",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "MDx Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "MALE",
        "summary": "40 Years to 85 Years · Male only"
      },
      "enrollment_count": 1000,
      "start_date": "2017-03-31",
      "completion_date": "2019-12-30",
      "has_results": false,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-10-30T19:47:49.628Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03082274"
    },
    {
      "nct_id": "NCT05197452",
      "title": "Increasing COVID-19 Testing in Chicago's African American Testing Desserts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COVID-19 Pandemic"
      ],
      "interventions": [
        {
          "name": "COVID-19 Testing",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2167,
      "start_date": "2021-03-23",
      "completion_date": "2022-11-18",
      "has_results": true,
      "last_update_posted_date": "2024-05-24",
      "last_synced_at": "2026-10-30T19:47:49.628Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05197452"
    },
    {
      "nct_id": "NCT03249350",
      "title": "Enhancing Adolescent Substance Abuse Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Substance Use Disorders"
      ],
      "interventions": [
        {
          "name": "Standard Contingency Management (CM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Enhanced Contingency Management (CM+)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Oregon Social Learning Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 129,
      "start_date": "2018-04-23",
      "completion_date": "2024-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-10-30T19:47:49.628Z",
      "location_count": 1,
      "location_summary": "Eugene, Oregon",
      "locations": [
        {
          "city": "Eugene",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03249350"
    },
    {
      "nct_id": "NCT01479842",
      "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "BTK inhibitor PCI-32765",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bendamustine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "pharmacogenomic studies",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Kami Maddocks, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2014-03-26",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-30T19:47:49.628Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01479842"
    },
    {
      "nct_id": "NCT04197713",
      "title": "Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Refractory Malignant Solid Neoplasm",
        "Unresectable Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Adavosertib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2020-06-30",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-30T19:47:49.628Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04197713"
    },
    {
      "nct_id": "NCT07504588",
      "title": "Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma",
        "Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma",
        "Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma",
        "Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma",
        "Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma",
        "Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Anti-VEGF Monoclonal Antibody",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Sacituzumab Govitecan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 87,
      "start_date": "2026-09-24",
      "completion_date": "2029-04-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-10-30T19:47:49.628Z",
      "location_count": 19,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Post Falls",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07504588"
    },
    {
      "nct_id": "NCT04345913",
      "title": "Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Unresectable Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Copanlisib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Eribulin Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2021-03-01",
      "completion_date": "2027-05-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-30T19:47:49.628Z",
      "location_count": 43,
      "location_summary": "Sacramento, California • Derby, Connecticut • Fairfield, Connecticut + 34 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Derby",
          "state": "Connecticut"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Glastonbury",
          "state": "Connecticut"
        },
        {
          "city": "Greenwich",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04345913"
    },
    {
      "nct_id": "NCT06766331",
      "title": "Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opioid Use Disorder",
        "HIV",
        "Hepatitis C Virus",
        "Gonorrhea",
        "Chlamydia",
        "Syphilis",
        "Sexually Transmitted Infection",
        "Integrated Care",
        "Medications for Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "Integrated care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2028-04-03",
      "completion_date": "2029-06-29",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-10-30T19:47:49.628Z",
      "location_count": 1,
      "location_summary": "Northport, New York",
      "locations": [
        {
          "city": "Northport",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06766331"
    }
  ]
}